Jaime Chu, MD
img_Jaime Chu
ASSOCIATE PROFESSOR | Pediatrics, Hepatology
Are you a patient?
Pediatrics, Pediatric Hepatology, Liver Transplantation, Pediatric Gastroenterology
Research Topics
Apoptosis/Cell Death, Biochemistry, Biomedical Sciences, Cancer, Cell Biology, Developmental Biology, Environmental Health, Fibrosis, Gastroenterology, Gene Regulation, Glycobiology, Inflammatory Bowel Disease (IBD), Metabolism, Obesity, Oncogenes, Organ Donation, Organogenesis, Patient Care, Patient Centered Outcomes Research, Pediatrics, Protein Structure/Function, Protein Translation, Regeneration, Signal Transduction, Translational Research, Transplantation, Tumor Suppressor Genes
Liver Disease and Development, Fibrosis, and Metabolism
Dr. Chu runs an R01-funded basic research group that focuses on how sugar metabolism pathways work together to sustain rapid cell growth in liver development and disease. Dr. Chu's long-term goal is to utilize collaborative science and integrate basic and clinical research towards improving our understanding of the mechanisms underlying pediatric liver disease and to apply this knowledge towards the development of much needed therapeutic options for children with liver disease. For more information, please see the Chu Lab website: http://labs.icahn.mssm.edu/chulab/

MD, New York University School of Medicine

BA, Harvard University

Residency, Pediatrics, Children's Memorial Hospital

Fellowship, Pediatric Gastroenterology, Children's Memorial Hospital

Fellowship, Pediatric Gastroenterology, Mount Sinai Hospital


American Board of Pediatrics



National Institutes of Health


AASLD Foundation Bridge Award

American Association for the Study of Liver Diseases Foundation


Gilead Sciences Research Scholars Program in Liver Disease Award

Gilead Sciences, Inc.


Art in Giving Research Scholar

The Rachel Molly Markoff Foundation


NIH K08 Mentored Clinical Scientist Development Award


Jaime Chu, MD, discusses Metabolic Disease

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Chu during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Albireo

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.